RESUMO
A preclinical canine model capable of predicting a compound's potential for pH-dependent absorption in humans was developed. This involved the surgical insertion of a gastrostomy feeding tube into the stomach of a beagle dog. The tube was sutured in position to allow frequent withdrawal of gastric fluid for pH measurement. Therefore, it was possible to measure pH in the stomach and assess the effect of gastric pH-modifying agents on the absorption of various test compounds. Fasted gastric pH in the dog showed considerable inter- and intra-animal variability. Pretreatment of pentagastrin (6 µg/kg intramuscularly) 20 min prior to test compound administration was determined to be adequate for simulating fasting stomach pH in humans. Pretreatment with famotidine [40 mg orally] 1 h prior to test compound administration was determined to be adequate for simulating human gastric pH when acid-reducing agents are coadministered. Pentagastrin and famotidine pretreatments were used to test two discovery compounds and distinct differences in their potential for pH-dependent absorption were observed. The model described herein can be used preclinically to screen out compounds, differentiate compounds, and support the assessment of various formulation- and prodrug-based strategies to mitigate the pH effect.
Assuntos
Avaliação Pré-Clínica de Medicamentos/métodos , Suco Gástrico/metabolismo , Mucosa Gástrica/metabolismo , Absorção Intestinal , Modelos Animais , Preparações Farmacêuticas/metabolismo , Farmacocinética , Administração Oral , Animais , Gorduras na Dieta/administração & dosagem , Cães , Famotidina/administração & dosagem , Jejum/metabolismo , Gastrostomia/instrumentação , Concentração de Íons de Hidrogênio , Injeções Intramusculares , Absorção Intestinal/efeitos dos fármacos , Masculino , Pentagastrina/administração & dosagem , Estômago/efeitos dos fármacos , Fatores de TempoRESUMO
A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor 1 (BMS-540215) was prepared in an effort to improve the aqueous solubility and oral bioavailability of the parent compound. These prodrugs were evaluated for their ability to liberate parent drug 1 in in vitro and in vivo systems. The l-alanine prodrug 8 (also known as brivanib alaninate/BMS-582664) was selected as a development candidate and is presently in phase II clinical trials.